SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today confirmed it will begin trading under the new symbol "IVF" at the market open on April 28, 2025. The CUSIP number for the Company's common stock will remain unchanged. The symbol change follows the Company's anno ...

Core Viewpoint - INVO Fertility, Inc. has announced a strategic separation of its fertility and oncology operations to maximize shareholder value, returning to a focus on the fertility marketplace and the distribution of its FDA-cleared INVOcell device [1][4][5] Group 1: Company Name Change and Structure - The company has been renamed to "INVO Fertility, Inc." effective April 14, 2025, with a new Nasdaq ticker symbol "IVF" to be implemented soon [2] - The separation will allow INVO Fertility to concentrate on building, acquiring, and operating fertility clinics, as well as distributing the INVOcell device [3][4] Group 2: Business Focus and Operations - INVO Fertility will leverage its existing operations in Wisconsin, Alabama, and Georgia to expand its network of fertility centers across the U.S. [5] - The company currently operates two INVO Centers and one IVF clinic, focusing on assisted reproductive technology (ART) care [6] Group 3: NAYA Therapeutics - NAYA Therapeutics will operate as a private company focusing on the clinical development of bifunctional antibodies, with the company retaining a minority stake to benefit from potential value appreciation [4][7] - NAYA Therapeutics has a portfolio that includes several bifunctional antibodies targeting various cancers, with clinical trials expected to commence in the near future [7]

Core Viewpoint - INVO Fertility, Inc. has announced a strategic separation of its fertility and oncology operations to maximize shareholder value, returning to a focus on the fertility marketplace and the distribution of its FDA-cleared INVOcell device [1][4][5]. Group 1: Company Name Change and Structure - The company has been renamed to "INVO Fertility, Inc." effective April 14, 2025, with a new Nasdaq ticker symbol "IVF" to be implemented shortly [2]. - The separation will allow INVO Fertility to concentrate on establishing, acquiring, and operating fertility clinics, as well as distributing the INVOcell device [3][4]. Group 2: Business Focus and Strategy - INVO Fertility aims to leverage its existing operations in Wisconsin, Alabama, and Georgia to expand its network of fertility centers across the U.S., capitalizing on a growing market opportunity [5]. - The company plans to divest a majority stake in its subsidiary, NAYA Therapeutics, while retaining a minority position to benefit from potential value appreciation in its bifunctional antibodies [4][5]. Group 3: NAYA Therapeutics Overview - NAYA Therapeutics will operate as a private company focused on the clinical development of bifunctional antibodies, with several promising candidates in its pipeline targeting oncology [7]. - The company’s lead candidate, NY-303, is set to enter a Phase I/IIa trial in H2 2025, targeting a significant portion of the current treatable market for hepatocellular carcinoma (HCC) [7].

SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 ...

SARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, proudly supports the U.S. President’s recent executive order aimed at reducing the cost of IVF and expanding access to fertility services. Th ...

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting sch ...

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common ...

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of commo ...

Core Insights - NAYA Biosciences is expanding its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent bifunctional antibody for treating hepatocellular carcinoma (HCC) and other solid tumors [1][4] Company Overview - NAYA Biosciences is a life science portfolio company focused on breakthrough treatments in oncology, autoimmune diseases, and women's health [5] - The company utilizes a hub & spoke model to efficiently acquire, develop, and partner assets, optimizing return on investment through scalable and profitable commercial revenues [5] Product Development - The new PD-1 x VEGF antibody, named NY-500, is designed to synergistically target PD-1 and VEGF, potentially improving T-cell infiltration and immune response in tumors [4] - NAYA is also developing NY-303, a GPC3-targeting bifunctional antibody, currently in a phase 1/2 clinical trial for HCC patients who do not respond to existing therapies [3][6] - NY-500 is expected to enter monotherapy phase 1/2a clinical trials in early 2026 [4][7] Market Potential - The PD-(L)1 market is projected to exceed $50 billion in 2025, indicating significant growth opportunities for NAYA's therapeutic candidates [4]

• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that it is expanding its bifunctional antibody pipeline to include ...